Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Smadar Avigad is active.

Publication


Featured researches published by Smadar Avigad.


Cytometry Part B-clinical Cytometry | 2010

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia

Drorit Luria; Eti Rosenthal; David M. Steinberg; Marina Safanaiev; Ninette Amariglio; Smadar Avigad; Batia Stark; Shai Izraeli

Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL). Multiparametric flow cytometry (FC) is a rapid and sensitive methodology for detection of MRD, applicable for most patients and is being incorporated in multicenter treatment protocols. The influence of different techniques and of individual interpretation of data on the interlaboratory variability in FC‐MRD determinations has not been described.


Digestive Diseases and Sciences | 2002

p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma.

Romy Zemel; Claud Koren; Larisa Bachmatove; Smadar Avigad; T. Ella Kaganovsky; Elimelech Okon; Ziv Ben-Ari; Franklin Grief; Merav Ben-Yehoyada; Yosef Shaul; Ran Tur-Kaspa

Abstractp73 is the first identified homolog of p53, but its function has not been established. Our study investigated the expression of p73 in liver tissue of patients with hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC). RT-PCR was performed on RNA extracted from tumorous and nontumorous liver tissue of HCV-associated HCC, and control tissue and the cDNA were sequenced. Anti-p73 polyclonal antibodies were used for protein analysis and immunohistochemistry, and patients sera were analyzed for anti-p73 antibodies by radioimmunoassay. Analysis of the p53 gene was performed by SSCP and RFLP-PCR. The p73 mRNA and protein were highly expressed and accumulated in HCC tissues. Immunohistochemical studies revealed significant immunoreactivity in the nuclei of HCC cells. No mutations were detected in the p73 gene or in p53, and no loss of heterozygosity of the p53 gene was found. Anti-p73 antibodies were detected in sera of HCC patients, but were not significantly different from that occurring in non-HCV or non-HCC patients. In conclusion, p73 protein is overexpressed and accumulates in the nuclei of HCV-associated HCCs and may play a role in HCC development.


European Journal of Cancer | 1997

Prognostic relevance of genetic alterations in the p32 region of chromosome 1 in neuroblastoma

Smadar Avigad; H Benyaminy; Y. Tamir; Drorit Luria; I. Yaniv; Jerry Stein; Batya Stark; Rina Zaizov

Thirty-six neuroblastomas were analysed for chromosome 1p alterations and their prognostic relevance. In 72% (26/36) of the patients, 1p alterations were identified in the tumours using 24 polymorphic loci ranging 1p22-1p36.3. LOH was identified in 25 children, and in 10 additional allelic imbalance was identified. In 1 child allelic imbalance was the sole alteration. Imbalance was termed as gain in intensity of one allele with or without reduction of the second allele (< 50%). The imbalance was identified in adjacent regions to the LOH. Two distinct regions of LOH were identified: 1p36.1-p36.3 and 1p31-p32. The common imbalance regions overlapped the common LOH regions. The children with LOH and imbalance had improved survival (100%) compared to the children with LOH only (26%) after 48 months of follow-up. The imbalance had an advantageous effect that is reflected by the improved outcome in children with other unfavourable clinical features.


Archive | 2011

Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse

Smadar Avigad; Isaac Yaniv


Archive | 2002

A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway

Smadar Avigad; Drorit Luria


Archive | 2017

PROGNOSTIC METHODS AND SYSTEMS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Smadar Avigad; Isaac Yaniv; Keren Shichrur


Archive | 2017

COMPOSITIONS FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA AND METHODS OF USE THEREOF

Smadar Avigad; Isaac Yaniv; Keren Shichrur


Annual General Meeting and 4th Neuroblastoma Research Symposium (SIOPEN), 24-27 November 2015 | 2015

High frequency of subclonal ALK mutations in high risk neuroblastoma patients. A SIOPEN study

Angela Bellini; Virginie Bernard; Eve Lapouble; Nathalie Clément; Gaëlle Pierron; Inge M. Ambros; Katleen De Preter; Nadine Van Roy; Ales Vicha; Valérie Combaret; David R. Betts; Marta Jeison; Smadar Avigad; Martina Morini; Luigi Varesio; Bárbara Marques; Annick Muhlethaler; Rosa Noguera; Ana P. Berbegall; Jaime Font de Mora; Peter F. Ambros; Ruth Ladenstein; Dominique Valteau-Couanet; Jean Michon; Olivier Delattre; Nick Bown; Deborah A. Tweddle; Gudrun Schleiermache


Archive | 2010

2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified

Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv


Archive | 2002

METHODE D'EVALUATION DE LA RECEPTIVITE POTENTIELLE D'UN SUJET A DES MEDICAMENTS ANTICANCEREUX AGISSANT SUR LA VOIE DE TRANSDUCTION DU SIGNAL RAS

Smadar Avigad; Drorit Luria

Collaboration


Dive into the Smadar Avigad's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Isaac Yaniv

Barzilai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge